NCT04130516: Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801

NCT04130516
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with ER+ cancer; Patients with thyroid cancer; Patients with prior treatment of GPER agonists (e.g. tamoxifen, raloxifene, estrogen replacement therapy); Patients with symptomatic unstable CNS metastases or leptomeningeal carcinomatosis – see trial for details
https://ClinicalTrials.gov/show/NCT04130516

Comments are closed.

Up ↑